- Exchange: NASDAQ GS
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Therapeutics
Isis Pharmaceuticals Inc
+ Add to WatchlistISIS:US
20.9800 USD 0.3400 1.65%As of 20:10:00 ET on 05/24/2013.
Snapshot for Isis Pharmaceuticals Inc (ISIS)
| Open: | 20.5500 | Day's Range: | 20.4300 - 21.0700 | Volume: | 878,047 |
|---|---|---|---|---|---|
| Previous Close: | 20.6400 | 52wk Range: | 7.5550 - 23.0300 | 1-Yr Rtn: | +111.92% |
Key Statistics for ISIS
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -0.5400 |
| Est. EPS (USD) (12/2013) | -0.7820 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 2,343.37 |
| Shares Outstanding (M) | 111.70 |
| 30 Day Average Volume | 1,779,950 |
| Price/Book (mrq) | 10.7143 |
| Price/Sale (ttm) | 17.3457 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 08/06/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ISIS
Company Profile & Key Executives for ISIS
Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
| Stanley T Crooke "Stan"Chairman/President/CEO/Co-Founder | B Lynne ParshallCOO/Secretary |
| Elizabeth L HougenSenior VP:Finance/CFO | Richard S GearySenior VP:Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ISIS News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page